Figure S6 from ⁸⁹Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors

S6. Pharmacokinetics and in vivo tumor expression. A. Tumor growth of syngeneic 4T1FLuc, CT26, and Panc02 tumors over the imaging period. B. Correlation of the average EMP2 histological score and mean %ID/cc in 4T1FLuc, CT26 and Panc02 tumors. C. Representative staining of EMP2 in 4T1FLuc, CT26 and Panc02 tumors. Magnification: 100m. D. Pharmacokinetics of the anti-EMP2 mAb as measured by western blot detection of the anti-Fc portion of the mAb. Mice were injected with 200 g or 20 g of the anti-EMP2 mAb. Cmax was defined by quantitation at t=2 hrs with the PK estimated at 140 hrs.